Alta Capital Management LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the third quarter, Holdings Channel reports. The fund owned 282,351 shares of the company’s stock after selling 3,262 shares during the period. Thermo Fisher Scientific comprises about 2.8% of Alta Capital Management LLC’s investment portfolio, making the stock its 13th largest position. Alta Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $44,910,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 1.0% in the second quarter. Vanguard Group Inc. now owns 24,236,706 shares of the company’s stock worth $3,581,215,000 after buying an additional 247,812 shares during the last quarter. FMR LLC increased its stake in Thermo Fisher Scientific by 11.3% in the second quarter. FMR LLC now owns 8,216,645 shares of the company’s stock worth $1,214,093,000 after buying an additional 834,858 shares during the last quarter. BlackRock Fund Advisors increased its stake in Thermo Fisher Scientific by 7.5% in the second quarter. BlackRock Fund Advisors now owns 5,834,133 shares of the company’s stock worth $862,051,000 after buying an additional 408,363 shares during the last quarter. Carmignac Gestion increased its stake in Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock worth $597,918,000 after buying an additional 763,421 shares during the last quarter. Finally, BlackRock Group LTD increased its stake in Thermo Fisher Scientific by 2.4% in the second quarter. BlackRock Group LTD now owns 3,513,706 shares of the company’s stock worth $519,185,000 after buying an additional 80,842 shares during the last quarter. Hedge funds and other institutional investors own 86.28% of the company’s stock.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) traded down 0.11% during mid-day trading on Wednesday, reaching $141.12. 208,486 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $149.29 and its 200 day moving average price is $151.92. The stock has a market capitalization of $55.75 billion, a PE ratio of 28.21 and a beta of 1.24. Thermo Fisher Scientific Inc. has a 12 month low of $119.75 and a 12 month high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, October 27th. The company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.97 by $0.06. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The company had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $4.39 billion. During the same quarter last year, the company posted $1.80 earnings per share. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Tuesday, December 13th. This represents a $0.60 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.00%.

TRADEMARK VIOLATION WARNING: “Alta Capital Management LLC Decreases Position in Thermo Fisher Scientific Inc. (TMO)” was first reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright laws. The correct version of this piece of content can be accessed at http://www.financial-market-news.com/alta-capital-management-llc-decreases-position-in-thermo-fisher-scientific-inc-tmo/1210618/.

Several equities research analysts have issued reports on the stock. Leerink Swann reiterated a “buy” rating and set a $175.00 price objective on shares of Thermo Fisher Scientific in a research note on Sunday, November 20th. Cleveland Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Friday, September 9th. Bank of America Corp. set a $180.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Friday, October 7th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $172.00 price objective for the company in a research note on Thursday, October 13th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 22nd. They set an “overweight” rating and a $180.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $164.37.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $151.17, for a total transaction of $4,535,100.00. Following the transaction, the chief executive officer now owns 308,647 shares in the company, valued at $46,658,166.99. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 28,797 shares of the stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the transaction, the chief executive officer now owns 307,444 shares in the company, valued at approximately $46,427,118.44. The disclosure for this sale can be found here. Company insiders own 0.52% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.